Why Alder thinks its late-comer migraine drug can succeed

Why Alder thinks its late-comer migraine drug can succeed

Source: 
Biopharma Dive
snippet: 

The odds are stacked against Alder BioPharmaceuticals, a company of about 200 based in Bothell, Washington. This February, Alder filed an application for U.S. approval of its drug eptinezumab, which blocks a protein called CGRP that's also the target of the therapies from its three would-be pharma rivals.